S. Tiong Ong
Belfast Health and Social Care Trust(GB)Duke University(US)Singapore General Hospital(SG)MRC Centre for Regenerative Medicine(GB)Duke Medical Center(US)Duke-NUS Medical School(SG)Royal Victoria Hospital(GB)Durham VA Medical Center(US)Centre for Inflammation Research(GB)Signature Research (United States)(US)University of Edinburgh(GB)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, Lung Cancer Treatments and Mutations, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer(2012)552 cited
- → Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor(2010)334 cited
- → Chemotherapy in malignant pleural mesothelioma. A review.(1996)226 cited
- FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.(1997)
- Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.(2003)
- → Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia(2019)144 cited
- → Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function(2013)140 cited